Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 273 followers
Latest posts
Last updated 1 day ago
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
1 day ago
Zepbound ® (tirzepatide) KwikPen ® for single-patient use available from Lilly at...
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
8 days ago
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS...
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
9 days ago
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs...
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
12 days ago
Used by millions of patients worldwide, the KwikPen® for single-patient use provides...
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
15 days ago
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free...
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
17 days ago
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met...
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
19 days ago
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will...
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
19 days ago
COLORADO SPRINGS, Colo., Feb. 16, 2026 /PRNewswire/ -- The United States Olympic...
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
19 days ago
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing...
Lilly to acquire Orna Therapeutics to advance cell therapies
26 days ago
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the...
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
about 1 month ago
Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume...
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
about 1 month ago
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines...